Investigational immunotherapy was safe, tolerableand showed some activity against melanoma
from Medical News Today
The investigational immunotherapeutic IMC-20D7S was safe, well tolerated, and showed signs of modest clinical activity for patients with advanced melanoma, according to results from a first-in-human phase I clinical trial. Wolchok explained that even though immunotherapy has significantly improved outcomes for some patients with advanced melanoma, many patients have tumors that do not respond to currently available treatments or have tumors that initially respond but then become resistant to them.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063